Phase II study of combination therapy with Irinotecan and S-1 in patients with progressive colorectal cancer after FOLFOX regimen - Phase II study of combination therapy with Irinotecan and S-1 in patients with progressive colorectal cancer after FOLFOX regimen(KSCC0702)

KSCC0 个研究点目标入组 56 人开始时间: 2008年8月29日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1. Administering antithrobotic drug within 7 days 2. Serious complications (renal failure or hepatic failure) 3. Serious drug hypersensitivity or a history of drug allergy 4. Active concomitant malignancy 5. Active infections 6. High blood pressure and diabetic that cannot be controlled 7. symptomatic or asymptomatic but treated heart disease 8. interstitial pnumonitis, pulmonary fibrosis or high-grade pulmonary emphysema 9. histry of mental disturbances or cerebrovascular attach 10. Fresh hemorrhage from digestive tube, intestines tube paralysis, intestinal obstruction and peptic ulcer 11. Plerral effusion, peritoneal fluid and pericardial fluid 12. Symptomatic brain metastasis 13. Water solubility diarrhea, in case of the patient who has a colostomy, diarrhea impairs daily life activity 14. Need to treatment with atazanavir sulfate or flucytosine 15. under coutinuous steroid therapy 16. Pregnant women, possibly pregnant women, wishing to become pregnant, and nursing mothers 17. on other clinical trial 18. Other conditions not suitable for this study

发起方

KSCC